(Q51389775)

English

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

scientific article published in October 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Vaishali Sanchorawala

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

author name string

Seldin DC

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Magnani B

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Skinner M

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Wright DG

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Bone Marrow Transplantation

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

36

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

597-600

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705106

0 references

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705106

21 January 2018

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705106

21 January 2018

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705106

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705106

21 January 2018

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705106

21 January 2018

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705106

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705106

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/16044137

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51389775&oldid=1465428225"